Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Genus stumbles as China and Brazil demand remains weak

Shares in Genus PLC (LSE:GNS), the animal genetics company, fell 4.5% despite reporting underlying profit slightly ahead of previous guidance in February.

Management of the FTSE 250-listed company said they expect adjusted profit before tax in actual currency to be between £58 mliion and £61 million.

PIC, its pig genetics arm, performed in-line with management's expectations, excluding China it "continues to perform robustly" but the Chinese porcine market "continues to be challenging".

ABS, the bovine genetics wing, showed improved profitability but continued to face lower volumes in the second half of the year, with persitently weak demand in several countries, most notably China and Brazil.

Currency headwinds are likely to result in a £5 million impact.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK